文献速递疼痛医学

植入式外周神经刺激治疗慢性疼痛的镇痛结局:系统综述与Meta分析(随访至24个月)

Implantable peripheral nerve stimulation for chronic pain: a systematic review and meta-analysis of analgesic outcomes up to 24 months.
PubMed 文献 · Reg Anesth Pain Med · 2025-11-05

该系统综述与Meta分析纳入106项研究共9272例成人慢性疼痛患者,评估植入式外周神经刺激(PNS)后疼痛强度变化。PNS在3、6、12及24个月均与疼痛强度大幅下降相关(Hedges' g 2.92~3.08,6个月为3.08),但主要结局证据确定性评为低。

要点

  • 植入式PNS在3、6、12、24个月均显著降低慢性疼痛强度,效应量较大。
  • 主要结局证据确定性低,源于观察性研究汇总、偏倚风险及异质性。
  • 企业资助和有利益冲突声明的研究报告效应量较小。

核心结论

  • 植入式PNS可为慢性疼痛提供持续且具有临床意义的镇痛,获益维持至24个月。

研究设计与样本

  • 系统综述与Meta分析,纳入106项研究共9272例成人慢性疼痛患者,接受植入式PNS治疗。

主要发现

  • 3个月疼痛强度变化Hedges' g 2.92(95%CI 2.62至3.21),6个月Hedges' g 3.08(95%CI 2.68至3.48),12个月Hedges' g 2.68(95%CI 2.30至3.05),24个月Hedges' g 2.08(95%CI 1.68至2.48),均p<0.001。
  • 亚组分析显示不同研究设计和装置类型间无差异,企业资助及有利益冲突声明的研究报告效应量较小。
  • 骨盆和上肢疼痛效应量最大,躯干疼痛效应量最小。

关键数值与推荐

  • 主要结局(基线至6个月疼痛强度变化)证据确定性按GRADE评为低,因汇总观察性研究、偏倚风险及统计、临床和方法学异质性。

临床怎么用

  • 结果支持植入式PNS更广泛的临床采用,并为支付覆盖和政策决策提供证据。

局限性

  • 主要结局证据确定性低,源于观察性研究汇总、偏倚风险及异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Peripheral nerve stimulation (PNS) has emerged as a promising neurostimulation modality, yet its effectiveness and durability for chronic pain remain uncertain. We conducted a systematic review and meta-analysis to evaluate changes in pain intensity following implantable PNS therapy. METHODS: Eligible studies included adults (≥18 years) with chronic pain treated with an implantable PNS system, and pain intensity was assessed at baseline and follow-up time points. The primary outcome was change in pain intensity from baseline to 6 months after PNS implantation. Secondary outcomes included changes in pain intensity at 3, 12 and 24 months after PNS implantation. Standardized mean differences (Hedges' g) were pooled using a random-effects model. RESULTS: A total of 106 studies comprising 9272 patients were included. PNS was associated with large, statistically significant reductions in pain intensity from baseline to all time points: 3 months (Hedges' g 2.92; 95% CI 2.62 to 3.21), 6 months (Hedges' g 3.08; 95% CI 2.68 to 3.48), 12 months (Hedges' g 2.68; 95% CI 2.30 to 3.05) and 24 months (Hedges' g 2.08; 95% CI 1.68 to 2.48) (all p<0.001). However, the certainty of evidence as assessed by the Grading of Recommendations Assessment, Development and Evaluation criteria was rated as low for the primary outcome, due to pooling from observational studies, risk of bias, and heterogeneity (statistical, clinical and methodological). Subgroup analyses revealed no differences by study design or device type, while smaller effect sizes were reported in industry-funded studies and those with declared conflicts of interest. The largest effect sizes were observed in pelvic and upper extremity pain, whereas the smallest in truncal pain. CONCLUSION: Implantable PNS provides persistent and clinically meaningful analgesia for chronic pain, with benefits sustained up to 24 months. These findings support broader clinical adoption and provide evidence to inform pay0r coverage and policy decisions.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. D'Souza RS, Her YF, Morsi M, et al. Implantable peripheral nerve stimulation for chronic pain: a systematic review and meta-analysis of analgesic outcomes up to 24 months. Reg Anesth Pain Med. 2025. PMID: 41193385. doi:10.1136/rapm-2025-107160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。